MX357293B - Anticuerpos anti-cd26 y usos de los mismos. - Google Patents

Anticuerpos anti-cd26 y usos de los mismos.

Info

Publication number
MX357293B
MX357293B MX2014014935A MX2014014935A MX357293B MX 357293 B MX357293 B MX 357293B MX 2014014935 A MX2014014935 A MX 2014014935A MX 2014014935 A MX2014014935 A MX 2014014935A MX 357293 B MX357293 B MX 357293B
Authority
MX
Mexico
Prior art keywords
present
provides
well
treating
antibodies
Prior art date
Application number
MX2014014935A
Other languages
English (en)
Other versions
MX2014014935A (es
Inventor
Francesco Di Naro Antonio
Original Assignee
Adienne S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48092884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX357293(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adienne S A filed Critical Adienne S A
Publication of MX2014014935A publication Critical patent/MX2014014935A/es
Publication of MX357293B publication Critical patent/MX357293B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)

Abstract

La presente invención se refiere a anticuerpos novedosos capaces de unirse a CD26, así como su uso como un medicamento. Además, la presente invención proporciona anticuerpos para uso en el tratamiento y/o prevención de rechazo inverso (GvHD) para uso en el tratamiento de anemia aplásica y/o para uso en promover el injertado después de transplante de blastocitos hematopoyéticos. Además, la presente invención proporciona composiciones farmacéuticas que comprenden por lo menos un anticuerpo de la presente invención así como proporcionar un kit de partes.
MX2014014935A 2013-02-19 2014-02-19 Anticuerpos anti-cd26 y usos de los mismos. MX357293B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13425029.9A EP2767549A1 (en) 2013-02-19 2013-02-19 Anti-CD26 antibodies and uses thereof
PCT/EP2014/053243 WO2014128168A1 (en) 2013-02-19 2014-02-19 Anti-cd26 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MX2014014935A MX2014014935A (es) 2015-06-17
MX357293B true MX357293B (es) 2018-07-04

Family

ID=48092884

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014935A MX357293B (es) 2013-02-19 2014-02-19 Anticuerpos anti-cd26 y usos de los mismos.

Country Status (26)

Country Link
US (2) US9376498B2 (es)
EP (3) EP2767549A1 (es)
JP (2) JP6240195B2 (es)
KR (1) KR101869589B1 (es)
CN (1) CN104684931B (es)
AU (1) AU2014220777B2 (es)
CA (1) CA2874422C (es)
CY (1) CY1121980T1 (es)
DK (1) DK2864359T3 (es)
ES (1) ES2738283T3 (es)
HR (1) HRP20191277T8 (es)
HU (1) HUE045150T2 (es)
IL (1) IL237244B (es)
LT (1) LT2864359T (es)
ME (1) ME03753B (es)
MX (1) MX357293B (es)
NZ (1) NZ631111A (es)
PL (1) PL2864359T3 (es)
PT (1) PT2864359T (es)
RS (1) RS59093B1 (es)
RU (1) RU2662933C2 (es)
SA (1) SA515360248B1 (es)
SI (1) SI2864359T1 (es)
SM (1) SMT201900408T1 (es)
TR (1) TR201910572T4 (es)
WO (1) WO2014128168A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11242399B2 (en) * 2013-02-19 2022-02-08 Adienne S.A. Anti-CD26 antibodies
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
PT3250202T (pt) * 2015-01-27 2021-06-17 Scipharm S A R L Composição para uso no aumento da eficácia do enxerto de células estaminais hematopoéticas após o transplante
US10630229B2 (en) * 2016-10-11 2020-04-21 Kevin Stapleton Panel mounting bracket with grounding mid-clamp and related methods
KR101960414B1 (ko) * 2016-11-11 2019-03-27 대한민국 사람 유래 dpp-4 유전자를 이용한 당뇨 질환 모델용 형질전환돼지 및 이의 용도
PL3729085T3 (pl) 2017-12-22 2026-02-16 Adienne S.A. Ilościowy sposób komórkowy do określania aktywności biologicznej ligandu anty-cd26
CN109709337B (zh) * 2018-12-28 2021-09-14 江苏众红生物工程创药研究院有限公司 人cd26的免疫组化检测试剂盒及其临床应用
CN117120475A (zh) * 2020-07-28 2023-11-24 阿迪安股份公司 特发性炎性肌病的治疗
JP2024517337A (ja) * 2021-05-13 2024-04-19 アディエンネ・ソチエタ・アノニマ 移植片対宿主病を処置する方法
AU2022273206A1 (en) * 2021-05-13 2024-01-04 Adienne S.A. Methods of treating dermatomyositis
CN116023491A (zh) * 2021-10-25 2023-04-28 江苏众红生物工程创药研究院有限公司 抗cd26抗体及其应用
CN118359716A (zh) * 2023-01-18 2024-07-19 江苏众红生物工程创药研究院有限公司 抗cd26抗体及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
NL9400309A (nl) * 1993-11-04 1995-06-01 Eurogenetics Nv Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26.
ES2269560T3 (es) 1998-04-15 2007-04-01 Genentech, Inc. Proteinas humanas que tienen una actividad antiproliferactiva in vitro.
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
JP2004533449A (ja) * 2001-05-11 2004-11-04 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム Ｃｄ２６を発現している細胞に関連する疾患の治療としての抗ｃｄ２６モノクローナル抗体
WO2006078161A1 (en) 2005-01-24 2006-07-27 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
CA2599734C (en) 2005-03-03 2014-01-28 Immunomedics, Inc. Humanized l243 antibodies
JP4997239B2 (ja) 2005-07-22 2012-08-08 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体およびその使用方法
CA2622608C (en) * 2005-09-14 2014-08-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
US8846393B2 (en) * 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
RU2331881C1 (ru) * 2007-03-09 2008-08-20 ГОУ ВПО "Красноярская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ определения риска развития атопических заболеваний у новорожденных детей
ES2663536T3 (es) 2008-09-26 2018-04-13 Oncomed Pharmaceuticals, Inc. Agentes que se unen a receptores frizzled y usos de los mismos
RU2645069C2 (ru) * 2010-08-18 2018-02-15 Авм Байотекнолоджи, Ллс Композиции и способы для ингибирования связывания стволовых клеток и клеток-предшественников с лимфоидной тканью и для регенерации зародышевых центров в лимфатических тканях
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof

Also Published As

Publication number Publication date
CA2874422A1 (en) 2014-08-28
JP2015529204A (ja) 2015-10-05
RS59093B1 (sr) 2019-09-30
IL237244B (en) 2019-09-26
CN104684931B (zh) 2019-08-27
KR101869589B1 (ko) 2018-06-20
DK2864359T3 (da) 2019-07-22
RU2662933C2 (ru) 2018-07-31
CA2874422C (en) 2021-10-19
PL2864359T3 (pl) 2019-11-29
JP2017221205A (ja) 2017-12-21
PT2864359T (pt) 2019-07-26
KR20150023419A (ko) 2015-03-05
EP2767549A1 (en) 2014-08-20
LT2864359T (lt) 2019-09-25
HRP20191277T8 (hr) 2019-11-01
EP2864359B1 (en) 2019-04-24
ES2738283T3 (es) 2020-01-21
JP6240195B2 (ja) 2017-11-29
EP2864359A1 (en) 2015-04-29
US10208126B2 (en) 2019-02-19
AU2014220777B2 (en) 2017-03-16
HK1205151A1 (en) 2015-12-11
US20160264676A1 (en) 2016-09-15
SA515360248B1 (ar) 2017-02-20
SMT201900408T1 (it) 2019-09-09
US20150017178A1 (en) 2015-01-15
EP3536711A1 (en) 2019-09-11
WO2014128168A1 (en) 2014-08-28
RU2014153440A (ru) 2016-07-20
TR201910572T4 (tr) 2019-08-21
IL237244A0 (en) 2015-04-30
BR112015002130A2 (pt) 2017-11-07
CN104684931A (zh) 2015-06-03
HRP20191277T1 (hr) 2019-10-18
ME03753B (me) 2021-04-20
US9376498B2 (en) 2016-06-28
NZ631111A (en) 2017-06-30
HUE045150T2 (hu) 2019-12-30
MX2014014935A (es) 2015-06-17
CY1121980T1 (el) 2020-10-14
SI2864359T1 (sl) 2019-09-30
AU2014220777A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
MX357293B (es) Anticuerpos anti-cd26 y usos de los mismos.
EA201400579A1 (ru) Антитела к il-36r
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
TN2015000050A1 (en) Methods of treating a tauopathy
EA201401204A1 (ru) Антитела к il-23p19
GEP201706733B (en) Anti-il-23 antibodies
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
NZ707086A (en) Anti-cd40 antibodies and methods of use
UA117072C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським
PH12013501255A1 (en) Anti-notch1 antibodies
EA201390660A1 (ru) Модифицированные никотиновые соединения и связанные способы
MX390739B (es) Composicion de hueso comprimido y metodo para usar la misma.
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
PH12014501176A1 (en) Anticoagulant reversal agents
MX392001B (es) Composiciones fertilizantes y métodos para hacer y utilizar las mismas.
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
ES2426017A2 (es) Microemulsión que comprende colagenasa y usos
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists
TN2014000207A1 (en) Anti il-36r antibodies

Legal Events

Date Code Title Description
FG Grant or registration